GlassScriptPhysician profile
Lara Gross
NPI 1811331705
$171,190.01
in general payments reported to CMS, 2019-2025
43 companies · $74K in 2025
The $74K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $1,211 · 2021: $3,883 · 2022: $11K · 2023: $17K · 2024: $63K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Honoraria: $46K · Consulting Fee: $31K · Food and Beverage: $12K · Travel and Lodging: $9,902 · Education: $65.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,655.74 |
| Honoraria | $46,036.00 |
| Consulting Fee | $30,821.50 |
| Food and Beverage | $11,820.61 |
| Travel and Lodging | $9,901.69 |
| Education | $65.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $52,909.87 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $32,589.97 | 2025 | Neffy |
| Genzyme Corporation | $19,732.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $17,036.24 | 2019-2025 | Dupixent |
| Incyte Corporation | $12,421.78 | 2022-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $9,741.58 | 2024 | Tapinarof |
| Astrazeneca Pharmaceuticals LP | $5,672.22 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Novartis Pharmaceuticals Corporation | $4,789.70 | 2023-2025 | Xolair |
| Regeneron Pharmaceuticals, INC. | $2,711.14 | 2023-2025 | Dupixent |
| Optinose US, INC. | $2,455.16 | 2023-2025 | |
| Blueprint Medicines Corporation | $2,364.24 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $2,103.27 | 2019-2025 | Xolair |
| Aquestive Therapeutics, INC. | $2,027.08 | 2025 | |
| Glaxosmithkline, LLC. | $1,265.67 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $464.14 | 2019-2025 | Xembify, Gamunex-C |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $395.06 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Kaleo, INC. | $333.79 | 2020-2024 | Auvi-Q |
| Octapharma USA, INC. | $235.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $204.23 | 2019-2022 | |
| Pharming Healthcare, INC. | $192.27 | 2019-2023 | Ruconest |
| Merck Sharp & Dohme LLC | $156.96 | 2023 | |
| Amgen INC. | $155.72 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.82 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $109.01 | 2019-2022 | |
| Organon LLC | $107.48 | 2025 | Vtama |
| Pfizer INC. | $99.99 | 2020-2023 | |
| Covis Pharma Gmbh | $85.67 | 2021 | |
| Genentech, INC. | $84.15 | 2019 | |
| Insmed, INC. | $83.73 | 2025 | Arikayce, Brinsupri |
| Hospira, INC. | $71.02 | 2024-2025 | |
| Shire North American Group INC | $68.31 | 2019 | |
| Abbvie INC. | $60.11 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $45.39 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $39.38 | 2024 | Ryaltris |
| Lilly USA, LLC | $38.78 | 2025 | Ebglyss, Taltz |
| Siemens Medical Solutions USA, INC. | $35.93 | 2025 | Immulite 1000 Immunoassay System |
| Ionis Pharmaceuticals, INC. | $26.32 | 2025 | Dawnzera |
| Gc Biopharma USA, INC. | $22.96 | 2025 | Alyglo |
| Azurity Pharmaceuticals, INC. | $21.94 | 2025 | Alvesco |
| Biocryst Pharmaceuticals, INC. | $21.80 | 2020 | |
| Leo Pharma INC. | $21.67 | 2023 | Adbry |
| Galderma Laboratories, L.P. | $21.56 | 2025 | Nemluvio |
| Almirall LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.